RadNet Inc. (NASDAQ:RDNT) – Analysts at Jefferies Financial Group issued their Q1 2019 EPS estimates for RadNet in a research report issued on Monday, November 12th, according to Zacks Investment Research. Jefferies Financial Group analyst B. Tanquilut forecasts that the medical research company will earn ($0.10) per share for the quarter. Jefferies Financial Group also issued estimates for RadNet’s Q2 2019 earnings at $0.10 EPS, Q4 2019 earnings at $0.35 EPS and FY2019 earnings at $0.54 EPS.

Several other equities analysts also recently weighed in on RDNT. Zacks Investment Research downgraded RadNet from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. BidaskClub downgraded RadNet from a “hold” rating to a “sell” rating in a research report on Thursday, August 30th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. RadNet presently has a consensus rating of “Buy” and a consensus target price of $15.50.

Shares of NASDAQ RDNT traded up $0.10 during trading hours on Wednesday, hitting $12.60. 184,646 shares of the company traded hands, compared to its average volume of 232,866. The company has a market cap of $610.83 million, a P/E ratio of 43.45, a P/E/G ratio of 4.66 and a beta of 0.42. The company has a debt-to-equity ratio of 4.56, a quick ratio of 1.12 and a current ratio of 1.12. RadNet has a 12 month low of $9.50 and a 12 month high of $16.54.

RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Friday, November 9th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.15 by ($0.05). RadNet had a positive return on equity of 14.62% and a negative net margin of 0.44%. The firm had revenue of $242.10 million during the quarter, compared to the consensus estimate of $240.07 million. During the same period in the previous year, the firm earned $0.12 EPS. The business’s revenue was up 6.4% compared to the same quarter last year.

A number of institutional investors and hedge funds have recently bought and sold shares of RDNT. Russell Investments Group Ltd. boosted its holdings in RadNet by 412.6% during the 1st quarter. Russell Investments Group Ltd. now owns 37,746 shares of the medical research company’s stock valued at $544,000 after acquiring an additional 30,383 shares during the period. Guggenheim Capital LLC lifted its holdings in shares of RadNet by 696.1% in the 1st quarter. Guggenheim Capital LLC now owns 102,581 shares of the medical research company’s stock worth $1,477,000 after buying an additional 89,695 shares during the period. Millennium Management LLC lifted its holdings in shares of RadNet by 927.5% in the 1st quarter. Millennium Management LLC now owns 295,806 shares of the medical research company’s stock worth $4,260,000 after buying an additional 267,016 shares during the period. Bessemer Group Inc. lifted its holdings in shares of RadNet by 10.1% in the 2nd quarter. Bessemer Group Inc. now owns 43,500 shares of the medical research company’s stock worth $653,000 after buying an additional 4,000 shares during the period. Finally, Sawgrass Asset Management LLC lifted its holdings in shares of RadNet by 37.7% in the 2nd quarter. Sawgrass Asset Management LLC now owns 55,080 shares of the medical research company’s stock worth $826,000 after buying an additional 15,090 shares during the period. Institutional investors own 61.47% of the company’s stock.

In related news, insider Norman R. Hames sold 14,000 shares of the business’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $15.59, for a total transaction of $218,260.00. Following the completion of the transaction, the insider now owns 589,000 shares in the company, valued at approximately $9,182,510. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey L. Linden sold 10,000 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $14.78, for a total value of $147,800.00. Following the transaction, the insider now owns 902,001 shares of the company’s stock, valued at approximately $13,331,574.78. The disclosure for this sale can be found here. Insiders own 7.56% of the company’s stock.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Story: What is the quiet period?

Get a free copy of the Zacks research report on RadNet (RDNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.